NCT05097053View on ClinicalTrials.gov

A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

PHASE4UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

July 31, 2022

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

MVC-COV1901(3 Months)

MVC-COV1901 vaccine after a 3-month Interval

BIOLOGICAL

MVC-COV1901(6 Months)

MVC-COV1901 vaccine after a 6-month Interval

Trial Locations (1)

Unknown

RECRUITING

Taoyuan General Hospital, Taoyuan District

Sponsors
All Listed Sponsors
collaborator

Medigen Vaccine Biologics Corp.

INDUSTRY

lead

Taoyuan General Hospital

OTHER_GOV

NCT05097053 - A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 | Biotech Hunter | Biotech Hunter